Trastuzumab,not lapatinib,has therapeutic effects on Chinese patients with HER2-positive cholangiocarcinoma  

作　　者：Hai-Bo Mou Wen-Dong Li Yan-Jun Shen Jun-Ping Shi Xiao-Di Guo Ming Yao Kai Wang Ting Zhang 

机构地区：[1]Department of Medical Oncology,Shulan(Hangzhou)Hospital,Hangzhou 310022,China [2]Department of Medical Oncology,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China [3]OrigiMed,Shanghai,China [4]Center of Precision Medicine,Shulan(Hangzhou)Hospital,Hangzhou 310022,China [5]Department of Bone Marrow,First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China

出　　处：《Hepatobiliary & Pancreatic Diseases International》2018年第5期477-479,共3页国际肝胆胰疾病杂志（英文版）

基　　金：supported by a grant from Department of Education of Zhejiang Province(Y201636437)

摘　　要：As a relatively uncommon orphan tumor with high mortality,biliary tract cancer(BTC)presents an aggressive course and heterogeneous clinical features[1].BTC patients present with advanced manifestations[2].Unfortunately,there has been little progress in the management of BTC.Most patients have inoperable lesions and must receive palliative therapy.Gemcitabine-based chemotherapy has been the only widely accepted first-line treatment for advanced BTC[3].Nevertheless,BTCs are often refractory to chemotherapeutic regimens,leading to a poor clinical outcome in these patients.Recently,with the rapid development of next generation sequencing(NGS)technologies,some actionable mutations such as those in IDH1,FGFR2,BRAF,HER2 genes,and unique molecular subsets in BTCs have been identified[4],and related targeted therapy against actionable mutations has been introduced into clinical practice as a promising therapeutic strategy[5].

关 键 词：BILIARY TRACT cancer(BTC) next generation sequencing(NGS) 

分 类 号：R[医药卫生]